IRVINE, Calif., March 15, 2010 (GLOBE NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO - News) today with great sadness announced the death of its Chairman and Chief Executive Officer, Lloyd H. Malchow. Mr. Malchow passed away Sunday evening, March 14. The company extends its deepest condolences to his family.
It had been announced on February 8 that Mr. Malchow was taking an indefinite medical leave of absence to undergo medical treatment for cancer. Mr. Malchow is survived by his wife and two daughters.
“Lloyd was an exceptional leader, business colleague and friend,” said John Buhler, SenoRx President, Chief Operating Officer and Acting Chief Executive Officer. “He leaves a legacy of excellence and accomplishment as a business leader. His SenoRx family will miss him tremendously. He will always be remembered for his passion and commitment to both his work and his family. Through his compassion and tenacity he inspired all of us to be our best.”
About SenoRx
SenoRx (Nasdaq:SENO - News) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(R) vacuum-assisted breast biopsy system and Contura(TM) MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx’s field sales organization serves over 2,000 breast diagnostic and treatment centers in the United States. In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. The company’s line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company’s website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3605
Contact:
SenoRx, Inc. Lila Churney, Director of Investor Relations 949.362.4800 ext.132
